STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.
Read the full articleYou might also wanna read
Beyond the Step Change: What GLP-1s Solved - and What They Didn’t
GLP-1 therapies have redefined what obesity pharmacotherapy can achieve, but efficacy is no longer the only battleground.
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
In this week’s Optimizer, we take a look at how health tech companies are starting to incorporate features ‘built for GLP-1’ users.
theverge.com·1mo ago
A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism
#Throwback 🧪 VIEWPOINT | A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals JL Trevaskis
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lowe
Comments
Sign in to join the conversation.
No comments yet. Be the first.